|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hassan LM, Mahmoud N, Miller AB, Iraj H,
Mohsen M, Majid J, Reza SM and Mojgan M: Evaluation of effect of
self-examination and physical examination on breast cancer. Breast.
24:487–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Curigliano G, Spitaleri G, Dettori M,
Locatelli M, Scarano E and Goldhirsch A: Vaccine immunotherapy in
breast cancer treatment: Promising, but still early. Expert Rev
Anticancer Ther. 7:1225–1241. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li SY, Li R, Chen YL, Xiong LK, Wang HL,
Rong L and Luo RC: Aberrant PTPRO methylation in tumor tissues as a
potential biomarker that predicts clinical outcomes in breast
cancer patients. BMC Genet. 15:672014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang X, Huang CJ, Yu GZ, Wang JJ, Wang R,
Li YM and Wu Q: Expression of group IIA phospholipase A2 is an
independent predictor of favorable outcome for patients with
gastric cancer. Hum Pathol. 44:2020–2027. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li S, Zhao X, Wu Z, Li Y, Zhu L, Cui B,
Dong X, Tian S, Hu F and Zhao Y: Polymorphisms in arachidonic acid
metabolism-related genes and the risk and prognosis of colorectal
cancer. Fam Cancer. 12:755–765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mirtti T, Laine VJ, Hiekkanen H, Hurme S,
Rowe O, Nevalainen TJ, Kallajoki M and Alanen K: Group IIA
phospholipase A as a prognostic marker in prostate cancer:
Relevance to clinicopathological variables and disease-specific
mortality. APMIS. 117:151–161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Menschikowski M, Hagelgans A, Nacke B,
Jandeck C, Mareninova OA, Asatryan L and Siegert G: Epigenetic
control of group V phospholipase A2 expression in human malignant
cells. Tumour Biol. 37:8097–8105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Quach ND, Arnold RD and Cummings BS:
Secretory phospholipase A2 enzymes as pharmacological targets for
treatment of disease. Biochem Pharmacol. 90:338–348. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jin Y, Yang F and Du L: Nanoassemblies
containing a fluorouracil/zidovudine glyceryl prodrug with
phospholipase A2-triggered drug release for cancer treatment.
Colloids Surf B Biointerfaces. 112:421–428. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu C, Sun Z, Li C, Guo R, Li L, Jin L,
Wan R and Li S: Urocortin affects migration of hepatic cancer cell
lines via differential regulation of cPLA2 and iPLA2. Cell Signal.
26:1125–1134. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mannello F, Qin W, Zhu W, Fabbri L, Tonti
GA and Sauter ER: Nipple aspirate fluids from women with breast
cancer contain increased levels of group IIa secretory
phospholipase A2. Breast Cancer Res Treat. 111:209–218. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kondo T: Inconvenient truth: Cancer
biomarker development by using proteomics. Biochim Biophys Acta.
1844:861–865. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai Q, Zhao Z, Antalis C, Yan L, Del
Priore G, Hamed AH, Stehman FB, Schilder JM and Xu Y: Elevated and
secreted phospholipase A2 activities as new potential
therapeutic targets in human epithelial ovarian cancer. FASEB J.
26:3306–3320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schneider AP II, Zainer CM, Kubat CK,
Mullen NK and Windisch AK: The breast cancer epidemic: 10 facts.
Linacre Q. 81:244–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lanfranchi AE and Fagan P: Breast cancer
and induced abortion: A comprehensive review of breast development
and pathophysiology, the epidemiologic literature, and proposal for
creation of databanks to elucidate all breast cancer risk factors.
Issues Law Med. 29:3–133. 2014.PubMed/NCBI
|
|
17
|
Linos E, Spanos D, Rosner BA, Linos K,
Hesketh T, Qu JD, Gao YT, Zheng W and Colditz GA: Effects of
reproductive and demographic changes on breast cancer incidence in
China: A modeling analysis. J Natl Cancer Inst. 100:1352–1360.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
World Medical Association, . World medical
association declaration of helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai H, Chiorean EG, Chiorean MV, Rex DK,
Robb BW, Hahn NM, Liu Z, Loehrer PJ, Harrison ML and Xu Y: Elevated
phospholipase A2 activities in plasma samples from multiple
cancers. PLoS One. 8:e570812013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sobin LH and Wittekind C: TNM
classification of malignant tumors. International Union Against
Cancer (UICC) (5th). 54–58. 1997.
|
|
21
|
Buhmeida A, Bendardaf R, Hilska M, Laine
J, Collan Y, Laato M, Syrjänen K and Pyrhönen S: PLA2 (group IIA
phospholipase A2) as a prognostic determinant in stage II
colorectal carcinoma. Ann Oncol. 20:1230–1235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamashita S, Yamashita J, Sakamoto K,
Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K and Ogawa M:
Increased expression of membrane-associated phospholipase A2 shows
malignant potential of human breast cancer cells. Cancer.
71:3058–3064. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lovett JL, Chima MA, Wexler JK, Arslanian
KJ, Friedman AB, Yousif CB and Strassmann BI: Oral contraceptives
cause evolutionarily novel increases in hormone exposure: A risk
factor for breast cancer. Evol Med Public Health. 2017:97–108.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Russo J, Moral R, Balogh GA, Mailo D and
Russo IH: The protective role of pregnancy in breast cancer. Breast
Cancer Res. 7:131–142. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kamińska M, Ciszewski T, Łopacka-Szatan K,
Miotła P and Starosławska E: Breast cancer risk factors. Prz
Menopauzalny. 14:196–202. 2015.PubMed/NCBI
|
|
26
|
Webb ML, Cady B, Michaelson JS, Bush DM,
Calvillo KZ, Kopans DB and Smith BL: A failure analysis of invasive
breast cancer: Most deaths from disease occur in women not
regularly screened. Cancer. 120:2839–2846. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Howell A: The emerging breast cancer
epidemic: Early diagnosis and treatment. Breast Cancer Res. 12
Suppl 4:S102010. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Killelea BK, Long JB, Chagpar AB, Ma X,
Wang R, Ross JS and Gross CP: Evolution of breast cancer screening
in the Medicare population: Clinical and economic implications. J
Natl Cancer Inst. 106:pii: dju1592014. View Article : Google Scholar
|
|
29
|
Indovina P, Marcelli E, Pentimalli F,
Tanganelli P, Tarro G and Giordano A: Mass spectrometry-based
proteomics: The road to lung cancer biomarker discovery. Mass
Spectrom Rev. 32:129–142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vendramini-Costa DB and Carvalho JE:
Molecular link mechanisms between inflammation and cancer. Curr
Pharm Des. 18:3831–3852. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gurel B, Lucia MS, Thompson IM Jr, Goodman
PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM,
Sutcliffe S, et al: Chronic inflammation in benign prostate tissue
is associated with high-grade prostate cancer in the placebo arm of
the prostate cancer prevention trial. Cancer Epidemiol Biomarkers
Prev. 23:847–856. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deivendran S, Marzook KH and Radhakrishna
Pillai M: The role of inflammation in cervical cancer. Adv Exp Med
Biol. 816:377–399. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Q, Tan Q, Zheng Y, Chen K, Qian C, Li
N, Wang Q and Cao X: Blockade of Fas signaling in breast cancer
cells suppresses tumor growth and metastasis via disruption of Fas
signaling-initiated cancer-related inflammation. J Biol Chem.
289:11522–11535. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hernández M, Martín R, García-Cubillas MD,
Maeso-Hernández P and Nieto ML: Secreted PLA2 induces proliferation
in astrocytoma through the EGF receptor: Another
inflammation-cancer link. Neuro Oncol. 12:1014–1023. 2010.
View Article : Google Scholar : PubMed/NCBI
|
